| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 152 | 2024 | 682 | 26.490 |
Why?
|
| Anti-HIV Agents | 40 | 2024 | 152 | 7.060 |
Why?
|
| Humans | 231 | 2024 | 18058 | 4.280 |
Why?
|
| CD4 Lymphocyte Count | 59 | 2024 | 176 | 4.130 |
Why?
|
| Neoplasms | 20 | 2024 | 464 | 4.110 |
Why?
|
| Adult | 152 | 2024 | 7696 | 4.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 27 | 2020 | 96 | 4.010 |
Why?
|
| Male | 171 | 2024 | 10173 | 3.940 |
Why?
|
| Acquired Immunodeficiency Syndrome | 15 | 2023 | 66 | 3.810 |
Why?
|
| Female | 172 | 2024 | 12838 | 3.670 |
Why?
|
| Middle Aged | 130 | 2024 | 8073 | 3.610 |
Why?
|
| Cohort Studies | 82 | 2024 | 2631 | 3.440 |
Why?
|
| Viral Load | 31 | 2022 | 132 | 3.260 |
Why?
|
| Anti-Retroviral Agents | 18 | 2023 | 80 | 3.170 |
Why?
|
| Uterine Cervical Neoplasms | 11 | 2022 | 123 | 2.830 |
Why?
|
| California | 43 | 2024 | 2327 | 2.200 |
Why?
|
| Mouth Neoplasms | 4 | 2020 | 9 | 2.160 |
Why?
|
| HIV-1 | 18 | 2017 | 72 | 2.150 |
Why?
|
| Hepatitis C | 10 | 2023 | 66 | 2.140 |
Why?
|
| Risk Factors | 53 | 2024 | 3394 | 2.110 |
Why?
|
| Transgender Persons | 11 | 2024 | 45 | 2.020 |
Why?
|
| Pre-Exposure Prophylaxis | 8 | 2024 | 18 | 1.970 |
Why?
|
| Critical Illness | 4 | 2015 | 53 | 1.930 |
Why?
|
| Alcohol Drinking | 7 | 2021 | 375 | 1.910 |
Why?
|
| Substance-Related Disorders | 11 | 2024 | 439 | 1.790 |
Why?
|
| Aged | 48 | 2024 | 6258 | 1.690 |
Why?
|
| Leukoplakia, Oral | 3 | 2020 | 3 | 1.650 |
Why?
|
| Continuity of Patient Care | 7 | 2022 | 113 | 1.620 |
Why?
|
| United States | 50 | 2024 | 4119 | 1.620 |
Why?
|
| Incidence | 33 | 2021 | 1297 | 1.620 |
Why?
|
| Life Expectancy | 4 | 2020 | 33 | 1.570 |
Why?
|
| Coinfection | 7 | 2023 | 30 | 1.550 |
Why?
|
| Delivery of Health Care, Integrated | 12 | 2021 | 552 | 1.520 |
Why?
|
| Papillomavirus Infections | 8 | 2022 | 131 | 1.440 |
Why?
|
| Papillomavirus Vaccines | 3 | 2020 | 119 | 1.390 |
Why?
|
| Critical Care | 3 | 2014 | 72 | 1.380 |
Why?
|
| Continental Population Groups | 3 | 2019 | 317 | 1.350 |
Why?
|
| Young Adult | 41 | 2023 | 2479 | 1.350 |
Why?
|
| Retrospective Studies | 31 | 2024 | 2498 | 1.310 |
Why?
|
| Smoking | 6 | 2021 | 465 | 1.300 |
Why?
|
| Drug Prescriptions | 6 | 2023 | 157 | 1.280 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 177 | 1.270 |
Why?
|
| Medication Adherence | 6 | 2020 | 255 | 1.270 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2017 | 55 | 1.260 |
Why?
|
| Healthcare Disparities | 5 | 2018 | 205 | 1.250 |
Why?
|
| Myocardial Infarction | 5 | 2024 | 251 | 1.200 |
Why?
|
| Sarcoma, Kaposi | 4 | 2021 | 13 | 1.150 |
Why?
|
| Laryngoscopy | 3 | 2015 | 3 | 1.140 |
Why?
|
| Pain | 8 | 2024 | 84 | 1.130 |
Why?
|
| Ethnic Groups | 5 | 2021 | 504 | 1.120 |
Why?
|
| Adolescent | 41 | 2024 | 3714 | 1.080 |
Why?
|
| Video-Assisted Surgery | 2 | 2015 | 2 | 1.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2020 | 21 | 1.040 |
Why?
|
| Intubation, Intratracheal | 2 | 2015 | 6 | 1.040 |
Why?
|
| Skin Neoplasms | 3 | 2017 | 64 | 1.040 |
Why?
|
| HIV | 10 | 2023 | 26 | 1.030 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2017 | 24 | 1.030 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 667 | 1.030 |
Why?
|
| Papillomaviridae | 6 | 2022 | 47 | 1.010 |
Why?
|
| Proportional Hazards Models | 21 | 2024 | 745 | 1.000 |
Why?
|
| Video Recording | 2 | 2014 | 12 | 1.000 |
Why?
|
| Internal Medicine | 2 | 2014 | 28 | 0.990 |
Why?
|
| Insurance, Health | 5 | 2020 | 221 | 0.990 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 23 | 0.990 |
Why?
|
| Bacteremia | 1 | 2024 | 15 | 0.980 |
Why?
|
| Antiviral Agents | 4 | 2022 | 96 | 0.980 |
Why?
|
| North America | 20 | 2024 | 42 | 0.980 |
Why?
|
| Lymphoma, AIDS-Related | 4 | 2012 | 18 | 0.970 |
Why?
|
| Streptococcal Infections | 1 | 2024 | 21 | 0.970 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 102 | 0.960 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 238 | 0.950 |
Why?
|
| Prevalence | 20 | 2024 | 892 | 0.940 |
Why?
|
| Primary Health Care | 6 | 2024 | 843 | 0.930 |
Why?
|
| Mass Screening | 8 | 2022 | 678 | 0.920 |
Why?
|
| Anus Neoplasms | 5 | 2020 | 26 | 0.920 |
Why?
|
| Program Evaluation | 2 | 2014 | 236 | 0.920 |
Why?
|
| Hallucinogens | 1 | 2024 | 23 | 0.910 |
Why?
|
| Mental Health | 7 | 2023 | 166 | 0.900 |
Why?
|
| HIV Seropositivity | 11 | 2017 | 31 | 0.900 |
Why?
|
| Cervical Intraepithelial Neoplasia | 3 | 2019 | 16 | 0.900 |
Why?
|
| Early Detection of Cancer | 8 | 2022 | 510 | 0.880 |
Why?
|
| Fractures, Bone | 1 | 2023 | 91 | 0.880 |
Why?
|
| Alcoholism | 4 | 2021 | 346 | 0.870 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 138 | 0.860 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2022 | 1 | 0.860 |
Why?
|
| Abdominal Wall | 1 | 2022 | 2 | 0.860 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 166 | 0.850 |
Why?
|
| African Continental Ancestry Group | 4 | 2018 | 165 | 0.840 |
Why?
|
| Cannabis | 1 | 2024 | 73 | 0.830 |
Why?
|
| RNA, Viral | 17 | 2021 | 62 | 0.830 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 613 | 0.820 |
Why?
|
| Health Services Accessibility | 6 | 2020 | 316 | 0.820 |
Why?
|
| Comorbidity | 11 | 2024 | 618 | 0.780 |
Why?
|
| Electronic Health Records | 6 | 2024 | 734 | 0.760 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 18 | 0.760 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 14 | 0.740 |
Why?
|
| Canada | 20 | 2023 | 66 | 0.730 |
Why?
|
| Unsafe Sex | 1 | 2020 | 19 | 0.730 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 48 | 0.730 |
Why?
|
| Condylomata Acuminata | 6 | 2009 | 23 | 0.710 |
Why?
|
| Risk Assessment | 12 | 2024 | 1137 | 0.710 |
Why?
|
| Prostatic Neoplasms | 4 | 2017 | 299 | 0.700 |
Why?
|
| Case-Control Studies | 10 | 2020 | 1164 | 0.700 |
Why?
|
| Treatment Outcome | 19 | 2019 | 1259 | 0.680 |
Why?
|
| Dementia | 1 | 2021 | 103 | 0.670 |
Why?
|
| Motivational Interviewing | 1 | 2019 | 32 | 0.670 |
Why?
|
| Sexual and Gender Minorities | 3 | 2024 | 27 | 0.670 |
Why?
|
| Text Messaging | 1 | 2019 | 30 | 0.670 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2015 | 25 | 0.660 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 1255 | 0.660 |
Why?
|
| Risk | 8 | 2021 | 552 | 0.650 |
Why?
|
| Smoking Cessation | 1 | 2020 | 198 | 0.640 |
Why?
|
| Patient Compliance | 8 | 2017 | 303 | 0.640 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 643 | 0.630 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2018 | 7 | 0.630 |
Why?
|
| Medical Record Linkage | 2 | 2015 | 43 | 0.630 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2016 | 17 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 2 | 2016 | 77 | 0.620 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2024 | 178 | 0.620 |
Why?
|
| Mental Disorders | 4 | 2023 | 290 | 0.620 |
Why?
|
| Quality of Health Care | 1 | 2020 | 346 | 0.620 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 257 | 0.610 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 15 | 0.610 |
Why?
|
| Anxiety | 5 | 2023 | 153 | 0.600 |
Why?
|
| End Stage Liver Disease | 4 | 2022 | 11 | 0.600 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.600 |
Why?
|
| HIV Protease Inhibitors | 3 | 2020 | 13 | 0.590 |
Why?
|
| Hepacivirus | 6 | 2023 | 51 | 0.590 |
Why?
|
| Heart Failure | 1 | 2022 | 391 | 0.590 |
Why?
|
| Age Factors | 12 | 2019 | 945 | 0.580 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 1956 | 0.580 |
Why?
|
| Pneumonia | 1 | 2017 | 54 | 0.570 |
Why?
|
| Syphilis | 2 | 2022 | 17 | 0.570 |
Why?
|
| Prospective Studies | 15 | 2022 | 1294 | 0.560 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 8 | 0.560 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 54 | 0.550 |
Why?
|
| Hepatitis B | 5 | 2023 | 43 | 0.550 |
Why?
|
| Age Distribution | 8 | 2021 | 257 | 0.550 |
Why?
|
| Dyslipidemias | 2 | 2024 | 63 | 0.540 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 80 | 0.540 |
Why?
|
| Hepatitis B, Chronic | 4 | 2022 | 27 | 0.540 |
Why?
|
| Prognosis | 10 | 2024 | 619 | 0.530 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1309 | 0.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 177 | 0.530 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 6 | 0.520 |
Why?
|
| Biomarkers, Tumor | 5 | 2017 | 144 | 0.520 |
Why?
|
| Endoscopy | 2 | 2014 | 10 | 0.520 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 14 | 0.510 |
Why?
|
| Registries | 8 | 2018 | 486 | 0.510 |
Why?
|
| Ablation Techniques | 1 | 2014 | 3 | 0.510 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 20 | 0.510 |
Why?
|
| Papilloma | 2 | 2004 | 2 | 0.470 |
Why?
|
| Liver Diseases | 4 | 2012 | 25 | 0.470 |
Why?
|
| Blood Vessels | 1 | 2013 | 1 | 0.470 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 4 | 0.470 |
Why?
|
| Depression | 4 | 2024 | 512 | 0.470 |
Why?
|
| Homosexuality, Male | 9 | 2024 | 38 | 0.470 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 11 | 0.470 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 116 | 0.460 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 20 | 0.460 |
Why?
|
| Barrett Esophagus | 1 | 2014 | 114 | 0.460 |
Why?
|
| Anemia | 2 | 2024 | 32 | 0.450 |
Why?
|
| Hepatitis C, Chronic | 3 | 2021 | 65 | 0.450 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 5 | 0.440 |
Why?
|
| Transsexualism | 3 | 2023 | 12 | 0.430 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 705 | 0.430 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2021 | 139 | 0.420 |
Why?
|
| Disease Progression | 6 | 2023 | 255 | 0.410 |
Why?
|
| Pandemics | 4 | 2023 | 293 | 0.410 |
Why?
|
| Stroke | 1 | 2014 | 306 | 0.400 |
Why?
|
| Sex Factors | 6 | 2024 | 634 | 0.400 |
Why?
|
| Nelfinavir | 1 | 2011 | 4 | 0.390 |
Why?
|
| Acne Vulgaris | 2 | 2021 | 8 | 0.380 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 25 | 0.380 |
Why?
|
| HIV Seronegativity | 4 | 2007 | 9 | 0.380 |
Why?
|
| Aging | 5 | 2022 | 159 | 0.370 |
Why?
|
| Liver Neoplasms | 4 | 2021 | 42 | 0.360 |
Why?
|
| Sexual Behavior | 4 | 2017 | 123 | 0.360 |
Why?
|
| European Continental Ancestry Group | 5 | 2018 | 559 | 0.350 |
Why?
|
| Gender Identity | 7 | 2024 | 41 | 0.350 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.340 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 45 | 0.330 |
Why?
|
| Erectile Dysfunction | 2 | 2019 | 25 | 0.330 |
Why?
|
| Models, Theoretical | 2 | 2019 | 73 | 0.320 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2020 | 51 | 0.320 |
Why?
|
| Tenofovir | 3 | 2023 | 18 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 13 | 0.320 |
Why?
|
| Hispanic Americans | 4 | 2021 | 431 | 0.310 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 86 | 0.310 |
Why?
|
| Logistic Models | 8 | 2018 | 953 | 0.300 |
Why?
|
| Hypertension | 3 | 2024 | 489 | 0.290 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 13 | 0.290 |
Why?
|
| Military Personnel | 2 | 2006 | 12 | 0.290 |
Why?
|
| Regression Analysis | 6 | 2015 | 319 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 83 | 0.290 |
Why?
|
| Prescriptions | 2 | 2024 | 28 | 0.290 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 118 | 0.290 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 7 | 0.280 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 7 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 1023 | 0.280 |
Why?
|
| Insurance Coverage | 3 | 2024 | 136 | 0.270 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 64 | 0.270 |
Why?
|
| Sexual Partners | 3 | 2020 | 37 | 0.260 |
Why?
|
| Time Factors | 10 | 2017 | 1114 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 123 | 0.250 |
Why?
|
| Immune Tolerance | 3 | 2017 | 6 | 0.250 |
Why?
|
| Body Mass Index | 4 | 2018 | 961 | 0.250 |
Why?
|
| Self-Injurious Behavior | 2 | 2023 | 45 | 0.250 |
Why?
|
| Erythrocyte Indices | 1 | 2024 | 2 | 0.250 |
Why?
|
| Condoms | 2 | 2020 | 32 | 0.250 |
Why?
|
| Insurance, Life | 1 | 2024 | 1 | 0.250 |
Why?
|
| Insurance, Disability | 1 | 2024 | 1 | 0.250 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 7 | 0.250 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2004 | 2 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 148 | 0.240 |
Why?
|
| Administration, Oral | 1 | 2024 | 81 | 0.240 |
Why?
|
| Demography | 4 | 2020 | 106 | 0.240 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2022 | 3 | 0.240 |
Why?
|
| Glomerular Filtration Rate | 5 | 2023 | 156 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 26 | 0.230 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 454 | 0.230 |
Why?
|
| Lymphoma | 2 | 2017 | 7 | 0.230 |
Why?
|
| Health Status Disparities | 2 | 2019 | 154 | 0.230 |
Why?
|
| Vaccination | 2 | 2020 | 664 | 0.230 |
Why?
|
| Survival Analysis | 5 | 2016 | 225 | 0.230 |
Why?
|
| Cognition | 1 | 2024 | 80 | 0.230 |
Why?
|
| Testosterone | 2 | 2021 | 22 | 0.230 |
Why?
|
| Laryngeal Neoplasms | 1 | 2003 | 2 | 0.230 |
Why?
|
| AIDS Serodiagnosis | 1 | 2003 | 10 | 0.220 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 22 | 0.220 |
Why?
|
| Raltegravir Potassium | 2 | 2022 | 9 | 0.220 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.220 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 595 | 0.220 |
Why?
|
| Depressive Disorder | 4 | 2021 | 233 | 0.220 |
Why?
|
| Genital Diseases, Female | 1 | 2002 | 9 | 0.220 |
Why?
|
| Gastrostomy | 1 | 2022 | 3 | 0.220 |
Why?
|
| Medicare | 3 | 2019 | 206 | 0.220 |
Why?
|
| Hormones | 1 | 2022 | 16 | 0.210 |
Why?
|
| Gonorrhea | 1 | 2022 | 17 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 25 | 0.210 |
Why?
|
| Patient Readmission | 1 | 2024 | 161 | 0.210 |
Why?
|
| Self Report | 1 | 2024 | 252 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 55 | 0.210 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 48 | 0.210 |
Why?
|
| Infant, Newborn | 7 | 2024 | 852 | 0.210 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 1346 | 0.200 |
Why?
|
| Immunosuppression | 2 | 2020 | 9 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 249 | 0.200 |
Why?
|
| Chronic Disease | 5 | 2020 | 462 | 0.200 |
Why?
|
| Genetic Variation | 2 | 2019 | 87 | 0.200 |
Why?
|
| Odds Ratio | 5 | 2017 | 692 | 0.200 |
Why?
|
| Bayes Theorem | 4 | 2022 | 69 | 0.200 |
Why?
|
| Biopsy | 4 | 2017 | 73 | 0.200 |
Why?
|
| Homeless Persons | 1 | 2021 | 26 | 0.200 |
Why?
|
| Research Design | 3 | 2020 | 393 | 0.200 |
Why?
|
| Housing | 1 | 2021 | 40 | 0.190 |
Why?
|
| Social Stigma | 1 | 2021 | 19 | 0.190 |
Why?
|
| Europe | 4 | 2024 | 38 | 0.190 |
Why?
|
| District of Columbia | 1 | 2020 | 18 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2011 | 6 | 0.190 |
Why?
|
| Reference Values | 3 | 2018 | 86 | 0.190 |
Why?
|
| Sex Distribution | 3 | 2016 | 192 | 0.190 |
Why?
|
| Weight Gain | 2 | 2020 | 180 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 526 | 0.190 |
Why?
|
| Validation Studies as Topic | 1 | 2020 | 12 | 0.190 |
Why?
|
| Benchmarking | 1 | 2020 | 45 | 0.190 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 103 | 0.190 |
Why?
|
| Pregnant Women | 1 | 2021 | 44 | 0.190 |
Why?
|
| Child | 12 | 2021 | 2519 | 0.190 |
Why?
|
| Computer User Training | 1 | 2000 | 2 | 0.180 |
Why?
|
| Computer Literacy | 1 | 2000 | 2 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 2 | 0.180 |
Why?
|
| Alcohol-Related Disorders | 1 | 2021 | 56 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 127 | 0.180 |
Why?
|
| Students, Medical | 1 | 2000 | 17 | 0.180 |
Why?
|
| Viremia | 3 | 2020 | 9 | 0.180 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 27 | 0.180 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 3 | 0.180 |
Why?
|
| SEER Program | 3 | 2017 | 100 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 351 | 0.180 |
Why?
|
| Biomarkers | 3 | 2017 | 306 | 0.180 |
Why?
|
| Diplopia | 1 | 1999 | 1 | 0.180 |
Why?
|
| Sensory Deprivation | 1 | 1999 | 1 | 0.180 |
Why?
|
| Vision, Binocular | 1 | 1999 | 1 | 0.180 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 445 | 0.180 |
Why?
|
| Macula Lutea | 1 | 1999 | 2 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 40 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 13 | 0.170 |
Why?
|
| Virus Replication | 2 | 2011 | 12 | 0.170 |
Why?
|
| Retinal Diseases | 1 | 1999 | 16 | 0.170 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 350 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 98 | 0.170 |
Why?
|
| Sigmoidoscopy | 1 | 2019 | 67 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 394 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 264 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2020 | 125 | 0.160 |
Why?
|
| Sex Reassignment Surgery | 1 | 2017 | 3 | 0.160 |
Why?
|
| Medical Records | 1 | 2018 | 108 | 0.160 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2014 | 7 | 0.160 |
Why?
|
| Adenoma | 1 | 2019 | 100 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2019 | 178 | 0.160 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 6 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 113 | 0.150 |
Why?
|
| Apoptosis | 2 | 2015 | 10 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 4 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2019 | 152 | 0.150 |
Why?
|
| Recurrence | 3 | 2012 | 186 | 0.150 |
Why?
|
| Transcriptome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 34 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 742 | 0.150 |
Why?
|
| Living Donors | 1 | 2017 | 3 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2017 | 4 | 0.150 |
Why?
|
| Prostatectomy | 1 | 2017 | 79 | 0.150 |
Why?
|
| Genomics | 1 | 2017 | 65 | 0.150 |
Why?
|
| African Americans | 4 | 2021 | 485 | 0.150 |
Why?
|
| Colonoscopy | 1 | 2019 | 265 | 0.150 |
Why?
|
| Colonic Pouches | 1 | 2016 | 1 | 0.140 |
Why?
|
| Anal Canal | 1 | 2016 | 7 | 0.140 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.140 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 10 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 25 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 330 | 0.140 |
Why?
|
| Patient Participation | 2 | 2015 | 143 | 0.140 |
Why?
|
| Medicaid | 1 | 2018 | 206 | 0.140 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 66 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 407 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2012 | 36 | 0.140 |
Why?
|
| Kallikreins | 1 | 2016 | 4 | 0.140 |
Why?
|
| Anxiety Disorders | 3 | 2022 | 91 | 0.140 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 114 | 0.140 |
Why?
|
| Internet | 2 | 2013 | 247 | 0.140 |
Why?
|
| Disease Management | 1 | 2016 | 143 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 4 | 0.130 |
Why?
|
| Macrophages | 1 | 2015 | 4 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Health Status | 1 | 2017 | 331 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2016 | 160 | 0.130 |
Why?
|
| APACHE | 1 | 2015 | 11 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2018 | 1428 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 17 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 4 | 0.130 |
Why?
|
| National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2014 | 5 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 6 | 0.130 |
Why?
|
| Pregnancy | 4 | 2021 | 1484 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 397 | 0.120 |
Why?
|
| Infant | 7 | 2022 | 1212 | 0.120 |
Why?
|
| Vaginal Smears | 4 | 2022 | 46 | 0.120 |
Why?
|
| Healthcare Financing | 1 | 2013 | 4 | 0.120 |
Why?
|
| Denmark | 2 | 2004 | 19 | 0.120 |
Why?
|
| Government Programs | 1 | 2013 | 11 | 0.120 |
Why?
|
| Leg | 1 | 2013 | 4 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2013 | 36 | 0.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 7 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2013 | 25 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 6 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 14 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 33 | 0.110 |
Why?
|
| Bile Ducts | 2 | 1983 | 3 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 13 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 57 | 0.110 |
Why?
|
| Office Visits | 1 | 2013 | 85 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 20 | 0.110 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 4 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 37 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 47 | 0.110 |
Why?
|
| Cell Count | 1 | 2012 | 10 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 55 | 0.100 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1985 | 4 | 0.100 |
Why?
|
| Patient Selection | 1 | 2013 | 194 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 2 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 6 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2011 | 21 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Drug Administration Schedule | 5 | 2010 | 97 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2012 | 86 | 0.100 |
Why?
|
| Analgesics | 1 | 2010 | 28 | 0.090 |
Why?
|
| State Health Plans | 1 | 2010 | 43 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 20 | 0.090 |
Why?
|
| DNA, Viral | 3 | 2023 | 17 | 0.090 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 4 | 0.090 |
Why?
|
| Organophosphonates | 1 | 2010 | 7 | 0.090 |
Why?
|
| Adenine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2010 | 49 | 0.090 |
Why?
|
| Appendicitis | 1 | 2009 | 16 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 27 | 0.090 |
Why?
|
| Health Policy | 2 | 2024 | 135 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 188 | 0.090 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 2 | 0.080 |
Why?
|
| Urologic Diseases | 1 | 2009 | 8 | 0.080 |
Why?
|
| Prescription Drugs | 1 | 2009 | 32 | 0.080 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 21 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ritonavir | 1 | 2008 | 7 | 0.080 |
Why?
|
| Pyridines | 1 | 2008 | 10 | 0.080 |
Why?
|
| Drug Overdose | 1 | 2010 | 57 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 839 | 0.080 |
Why?
|
| Genotype | 2 | 2011 | 251 | 0.080 |
Why?
|
| Triglycerides | 1 | 2009 | 86 | 0.080 |
Why?
|
| Mortality | 1 | 2009 | 121 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 124 | 0.080 |
Why?
|
| Anus Diseases | 2 | 2005 | 2 | 0.080 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 1990 | 2 | 0.080 |
Why?
|
| Creatinine | 2 | 2023 | 67 | 0.080 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 75 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2021 | 32 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 125 | 0.070 |
Why?
|
| Pharmacists | 1 | 2007 | 42 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2009 | 344 | 0.070 |
Why?
|
| Liver | 3 | 2019 | 33 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 44 | 0.070 |
Why?
|
| Muscle Contraction | 2 | 1997 | 4 | 0.070 |
Why?
|
| HIV Antibodies | 1 | 2006 | 4 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2007 | 113 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2019 | 12 | 0.070 |
Why?
|
| Long-Term Care | 3 | 2010 | 22 | 0.070 |
Why?
|
| Papanicolaou Test | 3 | 2016 | 34 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2017 | 270 | 0.060 |
Why?
|
| Drug Utilization | 3 | 2010 | 134 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 813 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2024 | 38 | 0.060 |
Why?
|
| Mutation | 2 | 2017 | 129 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 22 | 0.060 |
Why?
|
| Carcinoma | 1 | 2004 | 27 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 393 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2024 | 13 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2015 | 6 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 30 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 81 | 0.060 |
Why?
|
| Survival Rate | 2 | 2015 | 266 | 0.060 |
Why?
|
| Schools | 1 | 2024 | 88 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2003 | 17 | 0.060 |
Why?
|
| Military Medicine | 1 | 2003 | 1 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2022 | 18 | 0.060 |
Why?
|
| Kidney | 1 | 2023 | 53 | 0.050 |
Why?
|
| Rilpivirine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Darunavir | 1 | 2022 | 4 | 0.050 |
Why?
|
| Causality | 1 | 2022 | 43 | 0.050 |
Why?
|
| Cause of Death | 1 | 2023 | 181 | 0.050 |
Why?
|
| Bias | 1 | 2022 | 109 | 0.050 |
Why?
|
| Quality of Life | 2 | 2020 | 509 | 0.050 |
Why?
|
| Social Isolation | 1 | 2021 | 16 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 19 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 45 | 0.050 |
Why?
|
| Income | 1 | 2021 | 95 | 0.050 |
Why?
|
| San Francisco | 1 | 2020 | 67 | 0.050 |
Why?
|
| Social Class | 1 | 2021 | 125 | 0.050 |
Why?
|
| Respiratory System | 1 | 2020 | 4 | 0.050 |
Why?
|
| MEDLINE | 1 | 2000 | 1 | 0.050 |
Why?
|
| Oxazines | 1 | 2020 | 2 | 0.050 |
Why?
|
| Pyridones | 1 | 2020 | 7 | 0.050 |
Why?
|
| Piperazines | 1 | 2020 | 9 | 0.050 |
Why?
|
| New York | 1 | 2000 | 21 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2000 | 22 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2020 | 15 | 0.050 |
Why?
|
| Computer Communication Networks | 1 | 2000 | 18 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2000 | 17 | 0.050 |
Why?
|
| Poverty | 1 | 2021 | 177 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2019 | 4 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 158 | 0.040 |
Why?
|
| Eyeglasses | 1 | 1999 | 2 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 15 | 0.040 |
Why?
|
| South Africa | 1 | 2019 | 17 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 8 | 0.040 |
Why?
|
| Visual Acuity | 1 | 1999 | 20 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 17 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 276 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 4 | 0.040 |
Why?
|
| Gene Expression | 1 | 2019 | 23 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 9 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 41 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 43 | 0.040 |
Why?
|
| Patient Preference | 1 | 2019 | 49 | 0.040 |
Why?
|
| Melanocortins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2018 | 3 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 15 | 0.040 |
Why?
|
| Washington | 2 | 2010 | 384 | 0.040 |
Why?
|
| Alleles | 1 | 2018 | 93 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 30 | 0.040 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 11 | 0.040 |
Why?
|
| Georgia | 1 | 2018 | 43 | 0.040 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 32 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2018 | 80 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 27 | 0.040 |
Why?
|
| Graft Survival | 1 | 2017 | 3 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2017 | 6 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 23 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 38 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 79 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 1997 | 2 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1997 | 2 | 0.040 |
Why?
|
| Serotonin | 1 | 1997 | 6 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2017 | 25 | 0.040 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2009 | 97 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 13 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 29 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 112 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 7 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 28 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2017 | 267 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Developed Countries | 1 | 2016 | 4 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2016 | 40 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2016 | 23 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 5 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 101 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 118 | 0.030 |
Why?
|
| Glomerular Mesangium | 1 | 1995 | 1 | 0.030 |
Why?
|
| Ileum | 1 | 1975 | 1 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 1975 | 2 | 0.030 |
Why?
|
| Arginine Vasopressin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Health Maintenance Organizations | 2 | 2008 | 481 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1995 | 3 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 65 | 0.030 |
Why?
|
| Calcium | 1 | 1995 | 34 | 0.030 |
Why?
|
| Glucose | 1 | 1995 | 30 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 16 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 155 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2015 | 3 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 4 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 5 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 8 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 318 | 0.030 |
Why?
|
| Hepatitis A | 3 | 1985 | 10 | 0.030 |
Why?
|
| Crohn Disease | 2 | 1985 | 16 | 0.030 |
Why?
|
| Acute Disease | 2 | 2005 | 138 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 2 | 1977 | 34 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 92 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 1 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1993 | 2 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 129 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 160 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 8 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 3 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 6 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 15 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 7 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2012 | 11 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 36 | 0.030 |
Why?
|
| Hepatovirus | 2 | 1985 | 2 | 0.030 |
Why?
|
| Hepatitis B Antigens | 2 | 1985 | 2 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 328 | 0.030 |
Why?
|
| Coproporphyrins | 1 | 1990 | 1 | 0.020 |
Why?
|
| Porphyrins | 1 | 1990 | 1 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1990 | 3 | 0.020 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 1970 | 6 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1970 | 28 | 0.020 |
Why?
|
| Morphine | 1 | 2009 | 7 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Bisexuality | 1 | 2009 | 13 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2009 | 12 | 0.020 |
Why?
|
| Atazanavir Sulfate | 1 | 2008 | 5 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 184 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2008 | 53 | 0.020 |
Why?
|
| Hepatolenticular Degeneration | 2 | 1970 | 3 | 0.020 |
Why?
|
| Insulin | 1 | 2009 | 208 | 0.020 |
Why?
|
| Vasoconstriction | 2 | 1997 | 3 | 0.020 |
Why?
|
| Rats | 2 | 1997 | 28 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 289 | 0.020 |
Why?
|
| Animals | 2 | 1997 | 250 | 0.020 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 1 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1985 | 8 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 1985 | 6 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2007 | 248 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1985 | 3 | 0.020 |
Why?
|
| Growth Disorders | 1 | 1985 | 1 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 53 | 0.020 |
Why?
|
| Body Height | 1 | 1985 | 59 | 0.020 |
Why?
|
| Fistula | 1 | 1984 | 1 | 0.020 |
Why?
|
| Rectal Fistula | 1 | 1984 | 1 | 0.020 |
Why?
|
| Abscess | 1 | 1984 | 6 | 0.020 |
Why?
|
| Probability | 1 | 2004 | 86 | 0.010 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1983 | 1 | 0.010 |
Why?
|
| Cholestasis | 1 | 1983 | 1 | 0.010 |
Why?
|
| Diagnostic Techniques, Surgical | 1 | 1983 | 1 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1983 | 58 | 0.010 |
Why?
|
| Cystic Fibrosis | 2 | 1970 | 8 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1997 | 1 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 1997 | 1 | 0.010 |
Why?
|
| Theophylline | 1 | 1997 | 1 | 0.010 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1997 | 1 | 0.010 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1997 | 1 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1997 | 2 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1997 | 3 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1997 | 3 | 0.010 |
Why?
|
| Calcimycin | 1 | 1995 | 1 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 1995 | 1 | 0.010 |
Why?
|
| Endothelins | 1 | 1995 | 1 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1995 | 5 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 3 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 11 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 7 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 11 | 0.010 |
Why?
|
| Isomerism | 1 | 1990 | 3 | 0.010 |
Why?
|
| Syndrome | 1 | 1990 | 31 | 0.010 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 1970 | 1 | 0.010 |
Why?
|
| Galactosemias | 1 | 1970 | 1 | 0.010 |
Why?
|
| Bile | 1 | 1970 | 4 | 0.010 |
Why?
|
| Tyrosine | 1 | 1970 | 2 | 0.010 |
Why?
|
| India | 1 | 1970 | 12 | 0.010 |
Why?
|
| Celiac Disease | 1 | 1970 | 1 | 0.010 |
Why?
|
| Esophageal Atresia | 1 | 1970 | 1 | 0.010 |
Why?
|
| Hyperbilirubinemia, Hereditary | 1 | 1970 | 1 | 0.010 |
Why?
|
| Intestinal Atresia | 1 | 1970 | 1 | 0.010 |
Why?
|
| Megacolon | 1 | 1970 | 1 | 0.010 |
Why?
|
| Protein-Losing Enteropathies | 1 | 1970 | 1 | 0.010 |
Why?
|
| Biliary Tract | 1 | 1970 | 2 | 0.010 |
Why?
|
| Duodenal Diseases | 1 | 1970 | 3 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 1970 | 2 | 0.010 |
Why?
|
| Constipation | 1 | 1970 | 4 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 1970 | 14 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 1970 | 8 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1970 | 49 | 0.010 |
Why?
|
| Body Weight | 1 | 1970 | 216 | 0.010 |
Why?
|
| Fissure in Ano | 1 | 1984 | 1 | 0.000 |
Why?
|
| Proctocolitis | 1 | 1984 | 1 | 0.000 |
Why?
|
| Puberty | 1 | 1985 | 58 | 0.000 |
Why?
|